🇺🇸 Rituximab or biosimilar in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised Rituximab or biosimilar on 17 December 2020

Marketing authorisation

FDA — authorised 17 December 2020

Application: BLA761140
Marketing authorisation holder: AMGEN INC
Local brand name: RIABNI
Indication: INJECTABLE — INJECTION
Status: approved

Read official source →

Frequently asked questions

Is Rituximab or biosimilar approved in United States?

Yes. FDA authorised it on 17 December 2020.

Who is the marketing authorisation holder for Rituximab or biosimilar in United States?

AMGEN INC holds the US marketing authorisation.